scholarly journals Loss-of-function of Fbxo10, encoding a post-translational regulator of BCL2 in lymphomas, has no discernible effect on BCL2 or B lymphocyte accumulation in mice

PLoS ONE ◽  
2021 ◽  
Vol 16 (4) ◽  
pp. e0237830
Author(s):  
Etienne Masle-Farquhar ◽  
Amanda Russell ◽  
Yangguang Li ◽  
Fen Zhu ◽  
Lixin Rui ◽  
...  

Regulation of the anti-apoptotic BCL2 protein determines cell survival and is frequently abnormal in B cell lymphomas. An evolutionarily conserved post-translational mechanism for over-expression of BCL2 in human B cell lymphomas and the BCL2 paralogue CED-9 in Caenorhabditis elegans results from loss-of-function mutations in human FBXO10 and its C.elegans paralogue DRE-1, a BCL2/CED-9-binding subunit of the SKP-CULLIN-FBOX (SCF) ubiquitin ligase. Here, we tested the role of FBXO10 in BCL2 regulation by producing mice with two different CRISPR/Cas9-engineered Fbxo10 mutations: an Asp54Lys (E54K) missense mutation in the FBOX domain and a Cys55SerfsTer55 frameshift (fs) truncating mutation. Mice homozygous for either mutant allele were born at the expected Mendelian frequency and appeared normal in body weight and appearance as adults. Spleen B cells from homozygous mutant mice did not have increased BCL2 protein, nor were the numbers of mature B cells or germinal centre B cells increased as would be expected if BCL2 was increased. Other lymphocyte subsets that are also regulated by BCL2 levels also displayed no difference in frequency in homozygous Fbxo10 mutant mice. These results support one of two conclusions: either FBXO10 does not regulate BCL2 in mice, or it does so redundantly with other ubiquitin ligase complexes. Possible candidates for the latter include FBXO11 or ARTS-XIAP. The difference between the role of FBXO10 in regulating BCL2 protein levels in C. elegans and in human DLBCL, relative to single-gene deficient mouse leukocytes, should be further investigated.

2020 ◽  
Author(s):  
Etienne Masle-Farquhar ◽  
Amanda Russell ◽  
Yangguang Li ◽  
Fen Zhu ◽  
Lixin Rui ◽  
...  

AbstractRegulation of the anti-apoptotic BCL2 protein determines cell survival and is frequently abnormal in B cell lymphomas. An evolutionarily conserved post-translational mechanism for over-expression of BCL2 in human B cell lymphomas and the BCL2 paralogue CED-9 in Caenorhabditis elegans results from loss-of-function mutations in human FBXO10 and its C.elegans paralogue DRE-1, a BCL2/CED-9-binding subunit of the SKP-CULLIN-FBOX (SCF) ubiquitin ligase. Here, we tested the role of FBXO10 in BCL2 regulation by producing mice with two different CRISPR/Cas9-engineered Fbxo10 mutations: an Asp54Lys (E54K) missense mutation in the FBOX domain and a Cys55SerfsTer55 frameshift (fs) truncating mutation. Mice homozygous for either mutant allele were born at the expected Mendelian frequency and appeared normal in body weight and appearance as adults. Spleen B cells from homozygous mutant mice did not have increased BCL2 protein, nor were the numbers of mature B cells or germinal centre B cells increased as would be expected if BCL2 was increased. Other lymphocyte subsets that are also regulated by BCL2 levels also displayed no difference in frequency in homozygous Fbxo10 mutant mice. These results support one of two conclusions: either FBXO10 does not regulate BCL2 in mice, or it does so redundantly with other ubiquitin ligase complexes. Possible candidates for the latter include FBXO11 or ARTS-XIAP. The difference between the role of FBXO10 in regulating BCL2 protein levels in C. elegans and in human DLBCL, relative to single-gene deficient mouse leukocytes, should be further investigated.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 1538-1538
Author(s):  
Franziska Auer ◽  
Deborah Ingenhag ◽  
Isidro Sánchez-García ◽  
Arndt Borkhardt ◽  
Julia Hauer

Abstract Introduction: Activation induced cytidine deaminase (AID) mediates somatic hypermutation and class switch recombination in splenic germinal center B cells and is implicated in retaining central B cell tolerance in the bone marrow (BM) (Cantaert et al., Immunity, 2015). Moreover, there is recent in vitro evidence that AID is upregulated in precursor B cells after exposure to LPS, contributing to the clonal evolution of pB-ALL (Swaminathan et al., Nat Immunol, 2015) (Greaves M. and Müschen M., Cancer Discovery, 2015). These studies were carried out in pre-BII / early immature B cells, which are the first B cell compartments with detectable intrinsic AID expression. However a functional role of AID in pro-B cells is still controversially discussed and a functional role of AID in leukemogenesis remains speculative. We designed an in vivo model which allowed us the investigation of intrinsic Aid expression in tumor prone pro-B cells. Our data indicate that Aid is a gate keeper at the early stage of B cell development and its loss of function facilitates the development of pB-ALL. Methods: We crossed a Rag1 deficient tumor prone mouse model (p19Arf-/-/Rag1-/-) (Hauer et al., Blood, 2011) on an Aid deficient background to obtain Aid knockout (p19Arf-/-/Rag1-/-/Aid-/-) and heterozygous (p19Arf-/-/Rag1-/-/Aid+/-) mice. Healthy and diseased mice were characterized by immunohistochemistry, Flow cytometric analysis, genome and transcriptome profiling. Cell cycle analysis was performed with pro-B cells of healthy mice. Results: P19Arf-/-Rag1-/- mice display a B cell developmental arrest at the pro-B stage and develop pB-ALL at an incidence of 26 %. Surprisingly, an additional loss of Aid in these cells accelerated the pB-ALL incidence to 98 % (44/45, median onset 25 weeks). Moreover our model reproduces the dose dependent effect of AID on regulating B cell tolerance in humans, since Aid+/- mice on the same background displayed significant disease reduction (83 %, 15/18, median onset 33 weeks, Mantel-Cox Test p=0.0175). The leukemia displayed a pro-B cell phenotype (CD19+B220+ckit+IgM-) and manifested with splenomegaly, dissemination of blast cells to the BM, peripheral blood (PB) and spleen. Pro-B tumors from p19Arf-/-Rag1-/- mice expressed Aid on transcript (qRT-PCR) and protein (western blot) level, indicating that Aid expression is not restricted to CD19+ BM cells with co-expression of a functional IgM heavy chain product but rather occurs at earlier stages of B cell development. Again this effect was dose dependent, since in pB-ALLs of p19Arf-/-Rag1-/-Aid-/+ mice Aid expression was significantly reduced. To identify the second hit we performed whole exome sequencing of murine tumors, which revealed accumulation of recurrent somatic Jak3 (R653H, V670A) and Dnm2 (G397R) mutations. To extend these findings further, Sanger sequencing of these regions displayed a mutational pattern of somatic Jak3 mutations in 60 % of Aid+/- and 80 % of Aid-/-pB-ALLs, while Dnm2 was somatically mutated in 96 % of all pB-ALLs analyzed. The detected Jak3 variants are known to induce a constitutive active downstream signaling. Loss of function mutations in DNM2 can increase the IL-7R cell surface expression, which highlight the relevance of the IL7R signaling in the context of tumor progression. However we did not observe detectable Aid expression in healthy pro-B cells of p19Arf-/-Rag1-/- animals in line with findings from Cantaert et al. On the other hand loss of Aid expression accelerates the repopulation capacity starting at the pro-B cell compartment (Kuraoka et al., Proc Natl Acad Sci, 2011). In our model Aid loss produces a dose dependent increase in proliferation and BrdU assays of B220+ sorted pro-B cells of healthy mice from the different cohorts (30 % cells in S-Phase in p19Arf-/-Rag1-/-compared to 50 % S-Phase with additional Aid loss), although Aid expression is below the detection limit. Conclusion: We present in vivo evidence that Aid has a gate keeper function in pro-B cells, which allows aberrant IL-7 dependent pro-B cells without a functional receptor to be eliminated through Aid induction. This further extends the observation that Aid mediates the clearance of autoreactive early immature B-cell clones and is required to prevent pB-ALL. In this regard Aid overexpression but also loss of Aid expression can facilitate pB-ALL development. Disclosures No relevant conflicts of interest to declare.


mBio ◽  
2021 ◽  
Vol 12 (2) ◽  
Author(s):  
C. N. Jondle ◽  
K. E. Johnson ◽  
C. Aurubin ◽  
P. Sylvester ◽  
G. Xin ◽  
...  

ABSTRACT Gammaherpesviruses establish lifelong infection and are associated with a variety of cancers, including B cell lymphomas. These viruses manipulate the B cell differentiation process to establish lifelong infection in memory B cells. Specifically, gammaherpesviruses infect naive B cells and promote entry of both infected and uninfected naive B cells into germinal centers, where the virus usurps rapid proliferation of germinal center B cells to exponentially increase its cellular latent reservoir. In addition to facilitating the establishment of latent infection, germinal center B cells are thought to be the target of viral transformation. In this study, we have uncovered a novel proviral role of host interleukin 17A (IL-17A), a well-established antibacterial and antifungal factor. Loss of IL-17A signaling attenuated the establishment of chronic gammaherpesvirus infection and gammaherpesvirus-driven germinal center response in a route of inoculation-dependent manner. Further, IL-17A treatment directly supported gammaherpesvirus reactivation and de novo lytic infection. This study is the first demonstration of a multifaceted proviral role of IL-17 signaling. IMPORTANCE Gammaherpesviruses establish lifelong infections in a majority of humans and are associated with B cell lymphomas. IL-17A is a host cytokine that plays a well-established role in the clearance of bacterial and fungal infections; however, the role of IL-17A in viral infections is poorly understood. In this study, we show that IL-17A signaling promoted the establishment of chronic gammaherpesvirus infection following the mucosal route of infection, viral lytic replication, and reactivation from latency. Thus, our study unveils a novel proviral role of IL-17A signaling in gammaherpesvirus infection.


2021 ◽  
Author(s):  
Cesare Mazzaro ◽  
Luigino Dal Maso ◽  
Marcella Visentini ◽  
Anna Ermacora ◽  
Pietro Andreone ◽  
...  

1994 ◽  
Vol 179 (1) ◽  
pp. 221-228 ◽  
Author(s):  
G Fischer ◽  
S C Kent ◽  
L Joseph ◽  
D R Green ◽  
D W Scott

Treatment of the WEHI-2131 or CH31 B cell lymphomas with anti-mu or transforming growth factor (TGF)-beta leads to growth inhibition and subsequent cell death via apoptosis. Since anti-mu stimulates a transient increase in c-myc and c-fos transcription in these lymphomas, we examined the role of these proteins in growth regulation using antisense oligonucleotides. Herein, we demonstrate that antisense oligonucleotides for c-myc prevent both anti-mu- and TGF-beta-mediated growth inhibition in the CH31 and WEHI-231 B cell lymphomas, whereas antisense c-fos has no effect. Furthermore, antisense c-myc promotes the appearance of phosphorylated retinoblastoma protein in the presence of anti-mu and prevents the progression to apoptosis as measured by propidium iodide staining. Northern and Western analyses show that c-myc message and the levels of multiple myc proteins were maintained in the presence of antisense c-myc, results indicating that myc species are critical for the continuation of proliferation and the prevention of apoptosis. These data implicate c-myc in the negative signaling pathway of both TGF-beta and anti-mu.


Cell ◽  
1994 ◽  
Vol 77 (1) ◽  
pp. 133-143 ◽  
Author(s):  
Hajime Karasuyama ◽  
Antonius Rolink ◽  
Yoichi Shinkal ◽  
Faith Young ◽  
Frederick W. Alt ◽  
...  

Blood ◽  
2004 ◽  
Vol 104 (9) ◽  
pp. 2936-2939 ◽  
Author(s):  
Yulei Shen ◽  
Javeed Iqbal ◽  
James Z. Huang ◽  
Guimei Zhou ◽  
Wing C. Chan

Abstract The regulation of B-cell lymphoma 2 (BCL2) protein expression in germinal center (GC) B cells has been controversial. Previous reports have indicated posttranscriptional regulation plays a dominant role. However, a number of recent studies contradicted these reports. Using real-time polymerase chain reaction (PCR) and Standardized Reverse Transcriptase-PCR (StaRT-PCR), we measured the level of mRNA expression in GC, mantle zone (MNZ), and marginal zone (MGZ) cells from laser capture microdissection. Both quantitative RT-PCR measurements of microdissected GC cells from tonsils showed that GC cells had low expression of BCL2 transcripts commensurate with the low protein expression level. These results are in agreement with microarray studies on fluorescence-activated cell sorter (FACS)-sorted cells and microdissected GC cells. We also examined BCL2 mRNA and protein expression on a series of 30 cases of diffuse large B-cell lymphoma (DLBCL) and found, in general, a good correlation. The results suggested that BCL2 protein expression is regulated at the transcriptional level in normal B cells and in the neoplastic cells in most B-cell lymphoproliferative disorders.


2021 ◽  
Vol 27 ◽  
Author(s):  
Anja Steinmaurer ◽  
Isabella Wimmer ◽  
Thomas Berger ◽  
Paulus Stefan Rommer ◽  
Johann Sellner

: Significant progress has been made in understanding the immunopathogenesis of multiple sclerosis (MS) over recent years. Successful clinical trials with CD20-depleting monoclonal antibodies have corroborated the fundamental role of B cells in the pathogenesis of MS and reinforced the notion that cells of the B cell lineage are an attractive treatment target. Therapeutic inhibition of Bruton's tyrosine kinase (BTK), an enzyme involved in B cell and myeloid cell activation and function, is regarded as a next-generation approach that aims to attenuate both errant innate and adaptive immune functions. Moreover, brain-penetrant BTK inhibitors may impact compartmentalized inflammation and neurodegeneration within the central nervous system by targeting brain-resident B cells and microglia, respectively. Preclinical studies in animal models of MS corroborated an impact of BTK inhibition on meningeal inflammation and cortical demyelination. Notably, BTK inhibition attenuated the antigen-presenting capacity of B cells and the generation of encephalitogenic T cells. Evobrutinib, a selective oral BTK inhibitor, has been tested recently in a phase 2 study of patients with relapsing-remitting MS. The study met the primary endpoint of a significantly reduced cumulative number of Gadolinium-enhancing lesions under treatment with evobrutinib compared to placebo treatment. Thus, the results of ongoing phase 2 and 3 studies with evobrutinib, fenobrutinib, and tolebrutinib in relapsing-remitting and progressive MS are eagerly awaited. This review article introduces the physiological role of BTK, summarizes the pre-clinical and trial evidence, and addresses the potential beneficial effects of BTK inhibition in MS.


Sign in / Sign up

Export Citation Format

Share Document